

## HR 2113

Speeding Access to Already Approved Pharmaceuticals Act of 2017

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 20, 2017

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Apr 21, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/2113>

### Sponsor

**Name:** Rep. Stivers, Steve [R-OH-15]

**Party:** Republican • **State:** OH • **Chamber:** House

### Cosponsors (2 total)

| Cosponsor                | Party / State | Role | Date Joined  |
|--------------------------|---------------|------|--------------|
| Rep. Ryan, Tim [D-OH-13] | D · OH        |      | Apr 20, 2017 |
| Rep. Bacon, Don [R-NE-2] | R · NE        |      | May 16, 2017 |

### Committee Activity

| Committee                     | Chamber | Activity    | Date         |
|-------------------------------|---------|-------------|--------------|
| Energy and Commerce Committee | House   | Referred to | Apr 21, 2017 |

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Apr 20, 2017)

#### Speeding Access to Already Approved Pharmaceuticals Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to facilitate the development and expedite the review of a new drug, biological product, or medical device that has been approved in the European Union.

### Actions Timeline

- **Apr 21, 2017:** Referred to the Subcommittee on Health.
- **Apr 20, 2017:** Introduced in House
- **Apr 20, 2017:** Referred to the House Committee on Energy and Commerce